Skip to main content
Vera Therapeutics, Inc. logo

Vera Therapeutics, Inc. — Investor Relations & Filings

Ticker · VERA ISIN · US92337R1014 US Professional, scientific and technical activities
Open in API
Filings indexed 418 across all filing types
Latest filing 2022-08-23 Director's Dealing
Country US United States of America
Listing US VERA

About Vera Therapeutics, Inc.

https://veratx.com/

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological and rare diseases. The company's mission is to change the standard of care and improve patients' lives. Its lead product candidate is atacicept, a novel biologic molecule being developed for the treatment of IgA nephropathy (IgAN), a progressive autoimmune kidney disease. Vera Therapeutics aims to advance its pipeline of innovative therapies to address significant unmet medical needs within immunology.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2022-08-23 English
FORM 4 SUBMISSION
Director's Dealing
2022-08-23 English
FORM 4 SUBMISSION
Director's Dealing
2022-08-23 English
FORM 4 SUBMISSION
Director's Dealing
2022-08-15 English
10-Q
Interim / Quarterly Report Q2 2022
2022-08-10 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or updates. The text specifically mentions that the company issued a press release announcing its financial results for the quarter ended June 30, 2022, and that the press release is furnished as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release. The length of the document is 3595 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document that announces or furnishes a press release of financial results without including the full financial data should be classified as a Regulatory Filing (RNS), as it does not contain the full earnings release or interim report itself but rather a notice of it.
2022-08-10 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.